Turn Therapeutics (NASDAQ:TTRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) from a sell rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

Several other analysts also recently issued reports on the stock. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. WBB Securities reissued a “sell” rating and set a $10.00 price objective on shares of Turn Therapeutics in a research note on Monday, September 14th. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Lucid Cap Mkts raised Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Turn Therapeutics Trading Down 7.4%

NASDAQ:TTRX opened at $11.11 on Friday. Turn Therapeutics has a 52-week low of $2.57 and a 52-week high of $16.45. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83. The stock has a fifty day simple moving average of $11.50 and a 200-day simple moving average of $7.72. The company has a market capitalization of $330.97 million and a PE ratio of -38.31.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. On average, equities research analysts expect that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Tamar Securities LLC acquired a new position in Turn Therapeutics in the 4th quarter valued at $59,000. Bank of America Corp DE purchased a new position in shares of Turn Therapeutics during the 2nd quarter worth $103,000. Jefferies Financial Group Inc. purchased a new position in shares of Turn Therapeutics during the 2nd quarter worth $119,000. DDFG Inc lifted its stake in shares of Turn Therapeutics by 34.9% during the 1st quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after purchasing an additional 18,246 shares during the period. Finally, Bridgewater Advisors Inc. acquired a new stake in shares of Turn Therapeutics during the second quarter worth $242,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.